Hikma Pharmaceuticals Stock Rating Reaffirmed by JPMorgan Chase & Co. (HIK)
Hikma Pharmaceuticals (LON:HIK)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Thursday, AnalystRatings.Net reports.
Hikma Pharmaceuticals (LON:HIK) traded up 0.24% during mid-day trading on Thursday, hitting GBX 1260.00. 95,649 shares of the company’s stock traded hands. Hikma Pharmaceuticals has a 52-week low of GBX 783.50 and a 52-week high of GBX 1326.00. The stock’s 50-day moving average is GBX 1230. and its 200-day moving average is GBX 1136.. The company’s market cap is £2.491 billion.
A number of other analysts have also recently weighed in on HIK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Tuesday, December 17th. They now have a GBX 1,250 ($20.52) price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note to investors on Tuesday, December 10th. They now have a GBX 1,270 ($20.85) price target on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Hikma Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of GBX 1,177.46 ($19.33).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.